# Diabetes Research Hub — Monitor Report

**Run date:** 2026-06-28 (automated, unattended)
**Scope:** Review-only. No existing files were modified.
**Evidence note:** Per Research Doctrine, new external claims below are labeled with confidence. Hub-file findings are [Certain] (read directly from files); web items are [Likely] unless a primary source is cited.

---

## TL;DR (what's actionable)

1. **Day-over-day, nothing moved in the trial set** — the 06-27→06-28 snapshot diff is 0 new / 0 removed / 0 status changes / 0 new results. The interesting changes are all *quarter-scale* (since the 03-15 snapshot): +138 new trials, 46 dropped, 52 status changes.
2. **Two breaking FDA items the hub should log** (both real, both outside the strict 7-day window but high-impact): **Tzield/teplizumab** expanded indication (approved June 12, 2026) and **orforglipron/Foundayo** approval (April 1, 2026). The hub is already capturing the literature wave for both.
3. **PubMed key-therapy coverage is rich** — the latest pull caught the full ACHIEVE (orforglipron), REIMAGINE (CagriSema), TRANSCEND (retatrutide) Phase 3 readouts plus the teplizumab label-expansion notes. This is exactly the Tier-1 "Clinical Trial Intelligence + Literature Synthesis" signal we want.
4. **Stale data risk:** PubMed snapshot is from 06-26 (2 days old, fine) but the **gap analysis underlying data is from 06-23** and the hub flags **754 result files >14 days old**. Gap analysis is the lower-cost refresh — recommend re-running it.

---

## File System Status [Certain]

| File | Last modified | Size | Status |
|------|--------------|------|--------|
| hub_monitor_report.md | 2026-06-28 07:08 | 8 KB | Fresh |
| clinical_trials_latest.json | 2026-06-28 07:05 | 568 KB | Fresh (838 trials) |
| pubmed_recent_latest.json | 2026-06-26 07:05 | 128 KB | 2 days old — OK |
| literature_gap_report.md | 2026-06-27 08:08 | 12 KB | Fresh |
| literature_gap_data.json | 2026-06-23 16:09 | 132 KB | **5 days old** — underlying gap data |

All five expected script outputs are present. No missing files. Snapshot history is continuous through 2026-06-28 (trials) and 2026-06-26 (PubMed).

**Hub-wide flag:** `hub_monitor.py` reports **754 result files older than 14 days** out of 986 tracked. Most are paper-library abstracts/fulltext and dated dashboards — not all need refreshing, but the volume is worth a periodic prune.

---

## Clinical Trial Changes [Certain]

### Day-over-day (06-27 → 06-28)
Zero change across all metrics. No action needed today.

### Quarter-scale (since 03-15 snapshot, 746 → 838 trials)
- **+138 new trials**, **46 dropped**, **52 status changes**.
- Notable status transitions worth a tracker note:
  - `NCT01897688` (Northwestern islet transplant, Phase 3) → **COMPLETED**, results posted 2026-06-18.
  - `NCT06141941`, `NCT06728059` → **RECRUITING → COMPLETED** (the latter is a machine-learning bolus-priming AID study; results posted 2026-05-28).
  - Multiple Lilly/Novo Phase 3 programs moved **RECRUITING → ACTIVE_NOT_RECRUITING** (e.g. orforglipron `NCT06972472`/`NCT06993792`, oral-sema `NCT07271251`) — i.e. enrollment closing, readouts approaching.

### Key Phase 3 trials to keep watching (currently RECRUITING)
| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT04786262 | **Vertex** | **VX-880 / zimislecel** islet cell therapy, T1D (pivotal) |
| NCT06832410 | **Vertex** | VX-880 / zimislecel in T1D + kidney transplant |
| NCT07222137 / NCT07222332 | **Eli Lilly** | **Baricitinib** — delay/preserve beta-cell function in T1D (BARICADE) |
| NCT07088068 | **Sanofi** | **Teplizumab** vs placebo, Stage 3 T1D, ages 1–25 |
| NCT07076199 | **Novo Nordisk** | Insulin **icodec** weekly, T1D |
| NCT07564414 | **Novo Nordisk** | **CagriSema** dosing in obesity ± T2D |

47 Phase-3 trials are currently RECRUITING in the set. Note: there are **no zimislecel/VX-880 results posted yet** (`has_results=false`); Vertex regulatory submission is expected in 2026 per public reporting [Likely].

### Recently posted results (last ~30 days, worth a skim)
Mostly academic/device studies — Northwestern islet transplant (06-18), NYU personalized-diet T2D (06-18), Dexcom/Libre accuracy (06-17), Miami allogeneic MSC infusion (06-16). No big-pharma Phase 3 results newly posted in the last 7 days; the most recent industry result was Novo's insulin-icodec `NCT05813912` on 2026-06-03.

---

## PubMed Highlights [Certain]

Latest pull: **163 unique papers**, 16 domains, lookback 30 days (generated 06-26). Day-over-day snapshot diff (06-25→06-26): **+42 / −41 papers**.

### Cross-domain papers (highest value — appear in multiple alert domains)
- **[42345832]** *The Programmable Microbiome: Integrative AI and Multi-Omics Frameworks for Precision T2DM Management* — **3 domains** (AI/ML + Microbiome + Multi-Omics). Directly on top of Tier-1 "Multi-Omics Biomarker Integration." Highest-priority read.
- **[42336896]** *CRISPR-Cas9 knock-in of CMV US2 for hypoimmunogenic hiPSC lines* — Stem Cell Cure + Gene Therapy. Relevant to the VX-880/hypoimmune cell-therapy thread.
- **[42339860]** *The systems-medicine view of semaglutide* — GLP-1 + Multi-Omics.
- **[42332392] / [42295172]** Teplizumab (Tzield) indication notes — T1D Immunotherapy + Key Therapy. Corroborates the FDA item below.

### Key-therapy literature captured this cycle
- **Orforglipron:** ACHIEVE-2 (vs dapagliflozin, `42259339`), ACHIEVE-5 (added to glargine, `42251769`), pooled hepatic-safety analysis (`42338042`).
- **Retatrutide:** TRANSCEND-T2D-1 Phase 3 (`42250575`).
- **CagriSema:** REIMAGINE 1/2/3 Phase 3 trio (`42251860/59/56`).
- **Teplizumab:** CGM-based early treatment-response paper (`42267680`) + label notes.
- **zimislecel:** 0 papers this cycle (expected — pre-publication).

### Volume signal
High-activity domains: AI/ML (220 hits), GLP-1 New (216), Microbiome (159), Biomarker (155). Low/thin: LADA (7), Drug Repurposing (5), GLP-1 Pharmacogenomics (2). The thin domains overlap with our top gap-analysis targets (below) — consistent picture, not a data error.

---

## Gap Analysis Summary [Certain — data; BRONZE — classifications]

Top under-researched intersections (Gap Score, joint pubs), BRONZE validation per the gap report:

| Rank | Intersection | Gap | Joint pubs |
|------|-------------|-----|-----------|
| 1 | Beta Cell Regen × Health Equity | 100.0 | 0 |
| 2 | Insulin Resistance × Islet Transplant | 100.0 | 1 |
| 3 | Islet Transplant × Drug Repurposing | 100.0 | 0 |
| 4 | Islet Transplant × Health Equity | 100.0 | 0 |
| 5 | Gene Therapy × LADA | 100.0 | 0 |

### Alignment with Tier-1 contribution areas
Several top gaps sit squarely inside our Tier-1 lanes, which is where computational contribution is cheapest and highest-impact:
- **Drug Repurposing × {Islet Transplant, Glucokinase, LADA, Health Equity}** → Tier-1 #4 (Drug Repurposing Screening). Multiple 0-joint-pub intersections.
- **Health Equity × {Beta Cell Regen, Islet Transplant, Treg/CAR-T, Drug Repurposing}** → Tier-1 #6 (Epidemiological/Health Equity).
- The whole gap exercise → Tier-1 #2 (Literature Synthesis & Gap Analysis).

These are BRONZE (single analytical source). Doctrine path to SILVER: cross-reference each against Cochrane/PROSPERO to confirm no existing review covers the intersection, then expert classification.

---

## Breaking News (web check) [Likely]

Two items genuinely significant; both already echoed in the hub's PubMed pull, so they validate the pipeline:

- **Tzield (teplizumab) — expanded FDA approval, June 12, 2026.** Accelerated approval to delay insulin-production decline in children (reported ages 8–17 / "1 and older" across sources — worth confirming exact label) newly diagnosed with **Stage 3 T1D**; previously limited to delaying onset in Stage 2. First disease-modifying therapy for new-onset Stage 3 in this age group. Relevant to T1D Immunotherapy domain and the Sanofi teplizumab Phase 3 (`NCT07088068`) we're tracking. *(Outside strict 7-day window but high impact.)*
- **Orforglipron (Foundayo) — FDA approval, April 1, 2026.** First oral GLP-1 without food/water/timing restrictions; ATTAIN-1/2 Phase 3 basis. The hub captured ACHIEVE-2/5 diabetes data this cycle.

No genuinely new (last-7-day) Phase 3 readout or FDA action surfaced beyond routine coverage. ADA 2026 Scientific Sessions coverage is circulating — a dedicated ADA-abstract sweep may be worthwhile.

Sources:
- [Sanofi press release — Tzield Stage 3 approval](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650)
- [Breakthrough T1D — Tzield approval update](https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/)
- [Drugs.com — Foundayo (orforglipron) approval history](https://www.drugs.com/history/foundayo.html)
- [Managed Healthcare Executive — Vertex zimislecel Phase 3 underway](https://www.managedhealthcareexecutive.com/view/phase-3-trial-of-vertex-s-islet-cell-therapy-for-type-1-diabetes-in-under-way)
- [diaTribe — Top Diabetes News: ADA 2026](https://diatribe.org/diabetes-research/top-diabetes-news-ada-2026)

---

## Recommended Actions

1. **Re-run gap analysis** — underlying `literature_gap_data.json` is 5 days old (06-23). Low compute. `python project1_literature_gap_analysis.py`
2. **Log the two FDA items** in `Diabetes_Research_Tracker.xlsx`: Tzield Stage-3 expansion (June 12) and orforglipron approval, both tied to trials/domains already tracked.
3. **Read cross-domain paper [42345832]** (Programmable Microbiome / AI + Multi-Omics) — direct Tier-1 multi-omics relevance.
4. **Tracker note on trial transitions:** Northwestern islet Phase 3 (`NCT01897688`) COMPLETED with results 06-18; several Lilly/Novo Phase 3 programs closed enrollment this quarter (readouts approaching).
5. **Promote Drug-Repurposing gaps toward SILVER** — run the Cochrane/PROSPERO cross-check on the four 0-joint-pub Drug Repurposing intersections; they sit in Tier-1 #4.
6. **Optional housekeeping:** 754 result files >14 days old — consider a prune/archive pass on dated dashboards and abstracts.
7. **Consider an ADA-2026 abstract sweep** if not already covered by the PubMed alert domains.

---
*Generated by the Diabetes Hub automated monitor. Review-only run — no source files altered.*
